Viking Global Increases Esperion Therapeutics Stake ~ market folly

Monday, June 29, 2015

Viking Global Increases Esperion Therapeutics Stake

Andreas Halvorsen's hedge fund firm Viking Global has just filed a 13G with the SEC regarding Esperion Therapeutics (ESPR).  Viking now owns 5.9% of the company with over 1.33 million shares.

This is a sizable increase over the 136,919 shares they owned at the end of the first quarter.  This new filing was made due to activity on June 18th.

You can view additional portfolio activity from Viking Global here.

Per Google Finance, Esperion is "a pharmaceutical company focused on developing and commercializing oral, low-density lipoprotein cholesterol (LDL-cholesterol) lowering therapies for the treatment of patients with hypercholesterolemia and other cardio-metabolic risk markers. The Company's primary activities include conducting research and development activities, including nonclinical, preclinical and clinical testing, performing business and financial planning, recruiting personnel, and raising capital. ETC-1002, the Company's lead product candidate, is an orally available, once-daily small molecule designed to lower LDL-cholesterol levels and avoid the side effects associated with other LDL-cholesterol lowering therapies currently available. ETC-1002 is being developed for patients with hypercholesterolemia. One completed Phase IIb clinical study and a second that is nearing completion build upon a Phase I and Phase II clinical development program for ETC-1002."

blog comments powered by Disqus